Dominari (NASDAQ:DOMH) Stock Price Down 3.3% – Should You Sell?

Dominari Holdings Inc. (NASDAQ:DOMH) traded down 3.3% during mid-day trading on Monday . The company traded as low as $4.07 and last traded at $4.08. 120,145 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 204,480 shares. The stock had previously closed at $4.22.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Wall Street Zen downgraded shares of Dominari from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings cut shares of Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, January 12th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Dominari Stock Performance

The stock’s 50-day simple moving average is $4.42 and its two-hundred day simple moving average is $5.34. The stock has a market cap of $65.32 million, a price-to-earnings ratio of 0.73 and a beta of 0.56.

Dominari Announces Dividend

The firm also recently disclosed a dividend, which was paid on Monday, January 26th. Investors of record on Monday, January 5th were given a dividend of $0.445 per share. The ex-dividend date of this dividend was Monday, January 5th.

Insider Transactions at Dominari

In other Dominari news, COO Christopher Franklin Devall sold 45,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $3.85, for a total value of $173,250.00. Following the sale, the chief operating officer owned 145,702 shares of the company’s stock, valued at $560,952.70. This trade represents a 23.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last quarter, insiders sold 225,000 shares of company stock valued at $876,850. Company insiders own 29.92% of the company’s stock.

Hedge Funds Weigh In On Dominari

Several institutional investors and hedge funds have recently added to or reduced their stakes in DOMH. PFG Investments LLC bought a new stake in shares of Dominari in the 4th quarter worth approximately $53,000. Jane Street Group LLC acquired a new position in shares of Dominari in the second quarter valued at $158,000. Millennium Management LLC bought a new position in Dominari in the third quarter worth $213,000. Geode Capital Management LLC boosted its stake in Dominari by 2.9% during the second quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock worth $361,000 after buying an additional 1,866 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new position in Dominari in the third quarter worth about $771,000. 42.48% of the stock is currently owned by institutional investors.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.